I 1907
Alternative Names: I-1907Latest Information Update: 23 Mar 2022
At a glance
- Originator Boryung Pharmaceutical
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 31 Jan 2022 Discontinued - Preclinical for Diabetes mellitus in South Korea (Boryung Pharmaceutical pipeline, January 2022)
- 11 Feb 2021 I 1907 is available for licensing as of 11 Feb 2021. http://www.boryung.co.kr/eng/rnd/pipeline.do
- 11 Feb 2021 Preclinical trials in Diabetes mellitus in South Korea (unspecified route) (Boryung Pharmaceutical pipeline, February 2021)